<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465399</url>
  </required_header>
  <id_info>
    <org_study_id>FIBEA-01-EC/11/ALV</org_study_id>
    <secondary_id>2019-001167-75</secondary_id>
    <nct_id>NCT01465399</nct_id>
  </id_info>
  <brief_title>Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets</brief_title>
  <official_title>Randomized Clinical Trial, Controlled With Conventional Treatment, of Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-extraction Sockets in Simple Extractions of Molars in the Mandible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Eduardo Anitua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Eduardo Anitua</source>
  <brief_summary>
    <textblock>
      Immediately following tooth removal, a healing process begins that affects the eventual&#xD;
      alveolar bone volume and architecture of the alveolar ridge. Satisfactory and timely healing&#xD;
      are essential to obtain ideal functional reconstruction. Traumatic removal of a tooth, or a&#xD;
      poor healing response, may lead to excessive bone loss delaying tooth replacement, requiring&#xD;
      expensive and time-consuming reconstructive surgeries, or even the inability to be corrected.&#xD;
      The Plasma Rich in Growth Factors (PRGF-Endoret) has shown its therapeutic potential effect&#xD;
      to minimize the consequences of this aggression, promoting the regeneration of both hard and&#xD;
      soft involved tissues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of regenerated post-extraction sockets</measure>
    <time_frame>10-12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regenerated bone volume</measure>
    <time_frame>10-12 weeks</time_frame>
    <description>Measurement of the regenerated bone volume at final follow-up in relation to the initial post-extraction socket total volume measured by CT-Scanner and expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain (VAS)</measure>
    <time_frame>3, 7 and 15 days post-extraction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft Tissue Healing Index</measure>
    <time_frame>3, 7 and 15 days post-extraction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>3, 7 and 15 days post-extraction</time_frame>
    <description>Using a specific 0 to 3 Inflammation Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events or complications</measure>
    <time_frame>10-12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Post-Extraction Sockets Healing</condition>
  <arm_group>
    <arm_group_label>PRGF-Endoret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma Rich in Growth Factors PRGF-Endoret</intervention_name>
    <arm_group_label>PRGF-Endoret</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional closure of the lesion</intervention_name>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects of both genders and ≥ 18 years old&#xD;
&#xD;
          -  Indication of a simple one molar extraction in the mandible.&#xD;
&#xD;
          -  Possibility of observation during the follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unerupted third molars or with horizontal inclination.&#xD;
&#xD;
          -  Severe swelling prior to surgery in the areas designated for extraction.&#xD;
&#xD;
          -  Suffering an alteration or a serious hematologic disease.&#xD;
&#xD;
          -  Be currently undergoing or have received radiotherapy, chemotherapy or&#xD;
             immunosuppressive therapy, corticosteroids and/or anticoagulants 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  In regular treatment with NSAIDs or other anti-inflammatory drugs.&#xD;
&#xD;
          -  History of chronic hepatitis or cirrhosis.&#xD;
&#xD;
          -  Diabetes mellitus with poor metabolic control (glycosylated hemoglobin &gt;9%)&#xD;
&#xD;
          -  Patients undergoing dialysis.&#xD;
&#xD;
          -  Presence of malignant tumors, hemangiomas or angiomas in the extraction area.&#xD;
&#xD;
          -  History of ischemic heart disease in the last year.&#xD;
&#xD;
          -  Pregnancy or planned pregnancy during the study follow-up period.&#xD;
&#xD;
          -  Metabolic Bone Disease.&#xD;
&#xD;
          -  Patients taking bisphosphonates both orally and intravenously.&#xD;
&#xD;
          -  In general, any inability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Anitua, MD, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Dental Eduardo Anitua</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Dental Eduardo Anitua</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

